Psoriasis in Jordan: a single center experience

Similar documents
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

The Natural History of Psoriasis and Treatment Goals

Predicting the Response to Phototherapy for Psoriasis Patients

Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database

It is estimated that about 26,000 new cases of

Insights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

An otherwise healthy 12-year-old

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

Psoriasis. What is Psoriasis? What causes psoriasis? Medical Topics Psoriasis

Ustekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese

Psoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement

PSORIASIS PSORIASIS. Anatomic sites FACTS ABOUT PROSIASIS PSORIASIS 11/16/2017 STIGMATA OF PSORIASIS

Psoriasis: Causes, Symptoms, And Treatment

Psoriasiform Dermatitis in Children: Calling in the Troops

Supplementary Tables. Psoriasis a

Psoriasis. Overview. Epidemiology. Epidemiology 08/08/2015. Dr Nigel Burrows Consultant Dermatologist Addenbrooke s Hospital

Psoriasis: Therapeutic goals

A study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital

Psoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato

The Dermatology Clinical Effectiveness Research Network (DCERN): Early Findings for Psoriasis

Cigna Drug and Biologic Coverage Policy

COMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE

Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar

Horizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524

Supplementary Appendix

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009

Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial

PSORIASIS BEST PRACTICE IN MANAGEMENT

Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

Corporate Medical Policy

Treatment Changes in PaMents with Moderate-to- Severe Psoriasis: A RetrospecMve Chart Review

2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:

Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798

A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C

Topical Calcipotriol Algorithm

Psoriasis is a chronic, inflammatory, Prescribing in children

Follow this and additional works at: Part of the Medicine and Health Sciences Commons

Obesity and psoriasis: body weight and body mass index influence the response to biological treatment

Contemporary Management of Moderate to Severe Plaque Psoriasis

Original Policy Date

A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients

TRANSPARENCY COMMITTEE OPINION. 26 April 2006

UvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication

Psoriasis. Causes of Psoriasis

Etanercept: a new option in paediatric plaque psoriasis

A hospital based study to assess the prevalence of cardiovascular risk factors among patients of chronic plaque psoriasis

Effects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

Comparison of the efficacy of PUVA versus BBUVB in the treatment of psoriasis vulgaris

Psoriasis: A Therapeutic Update. Presenter: Christine Moussa, PGY-4 Program Director: Stephen Kessler, D.O. Alta Dermatology/LECOM

STUDY. Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis

What is Psoriasis? Common Areas Affected. Type Who Does it Affect Characteristics

PHARMACY POLICY STATEMENT Ohio Medicaid

Elements of Successful PBS Applications. Barbara Radulski RN. Copyright

Citation for the original published paper (version of record):

Use of medical record databases to study psoriasis

Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis

Josephine Mauskopf Miny Samuel Doreen McBride Usha G. Mallya Steven R. Feldman

COMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW

Comparative Efficacy of Topical Calcipotriol (0.005%) Versus Topical Corticosteroid (Betamethasone 0.1%) in Treating Plaque Type Psoriasis

Horizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652

Rotating night shift work and risk of psoriasis in US women

Horizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209

Evaluation of Asthma Management in Middle EAst North Africa Adult population

BJD. Summary. British Journal of Dermatology THERAPEUTICS

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

What s new in psoriasis? An analysis of guidelines and systematic reviews published in

Dermatologists Practices and Attitudes towards the Management of Moderate to Severe Psoriasis in Riyadh City, Saudi Arabia

Light Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.

Treatment for Psoriasis with Modified Goeckerman Regimen -One Year Experience in Southern Taiwan-

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

Subject: Guselkumab (Tremfya ) Injection

Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis

This PDF is available for free download from a site hosted by Medknow Publications

Pediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.

Clinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18

Psoriasis: an update for the Internist

QUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS

PSORIASIS AND COMORBIDITIES

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea

TREATMENT OPTIONS FOR PSORIASIS. Sandra Hanlon Dermatology Senior Charge Nurse NHS Ayrshire and Arran 07/03/17

COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS

The retrospective evaluation of clinical and sociodemographic features of patients with psoriasis

STUDY. Prevalence and Treatment of Psoriasis in the United Kingdom

Original article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis

DERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT

Serum proteins and Alkaline Phosphatase in Psoriasis: A case-control study

PUVA: Shall we still use it for psoriasis in 2019?

Assessment of Obesity in Chronic Plaque Psoriasis Patients in Comparison with the Control Group

Volume 7, Edition 1 / Winter 07 93

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases

Clinico-epidemiological profile, including body mass index of Malaysian children with psoriasis

The Treatment Toolbox for Severe Pediatric Psoriasis

Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis

THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS

Transcription:

Psoriasis in Jordan: a single center experience Shefaa Almashagbeh MD *, Deifallah Alsharari MD *, Hayat Khasawneh MD *, Diana Aljammal * MD, Hamzeh Al-housamieh MD* ABSTRACT Objectives: To evaluate the demographics, therapeutic protocols, risk factors and co-morbidities of psoriasis in one hospital in Jordan's public military health sector. Methods: Our study included 350 adult patients, of both genders, aged 19-75 years, diagnosed with psoriasis by dermatologists. The demographics, therapeutic protocols, risk factors and co-morbidities were assessed. Psoriasis was classified as severe, moderate, and mild forms depending on the psoriasis area severity index (PASI) score, which was used to assess the severity of psoriatic lesions based on area coverage and plaque appearance, a PASI <5 is a mild psoriasis, a PASI <10 is a moderate, and a PASI >10 is a severe psoriasis. We collected information on skin disorders and infections, chronic diseases, pregnancy, stress, obesity, smoking status and drug use (beta-blockers, ACE inhibitors, antimalarial, NSAIDs, lithium, interferon's, tetracycline's and penicillin.). The study was approved by the ethics and research review board committee of the Royal Medical Services. The patients' information was used for the study during a period of 4 years from Jan 2012 to Jan 201 at Prince Rashid Military Hospital, Irbid, Jordan. Results: Psoriasis was more prevalent in men and most prevalent in the age group 8-75 years. The prevalence in both genders increased with increasing age. 94.9% of patients were treated with topical corticosteroids and 12.9 % of patients had systemic treatment. Psoriatic patients experienced increased co-morbidities of diabetes mellitus and hypercholesterolemia. Patients with previous skin disorders (OR, 3.1 [95% CI, 2.9-3.8]) and skin infection (OR, 1.7 [95% CI, 1.5-1.8]), during the last year, had the highest risk of having psoriasis. Other risk factors include Smoking, obesity, stress, depression and skin trauma. Conclusion: The number of Jordanian psoriatic patients presenting to public health military sector hospitals is more in males than in females and the number increased markedly in patients aged 8-75 years. Key words: Co-morbidities, Epidemiology, Jordan, Psoriasis. JRMS June 2017; 24(2):-10/DOI: 10.1281/003935 Introduction Genetic and environmental factors affect the pathogenesis of psoriasis. Geographic site, gender and age influence the epidemiology of psoriasis. Patient information can clarify risk From the Department of: *Dermatology Department, King Hussein Medical Center, Amman, Jordan. Correspondence should be addressed to Dr. Shefaa Almashagbeh. Email: dr.shefa_almashqbeh @ yahoo.com Manuscript received Oct, 201. Accepted March 1, 2017. factors for disease severity. Psoriasis is a chronic, immunological and inflammatory disease of the skin and joints, with systemic implications, which affects 1-3% of the world s population. (1) A Frequency rate of 0.4 per 100 000 person-years was recorded in the

United States of America (prevalence 2.2-3.15%, prevalence in African Americans is 1.3%). (1) Psoriasis is subjected to flares or remissions with many different variations and scores of intensity. It may be symptomatic throughout life and may be progressive with age or wane in its severity. Psoriasis is the most frequent chronic disease of the skin, often debilitating, with high epidermal turnover rate and epidermal hyperplasia. The epidemiology is influenced by risk factors including skin infection, skin disorders, smoking, obesity and high body mass index, heavy alcohol consumption, stress and depression. Clinical features are cyclical, peaking during young adulthood (1 to 22 years of age) and during older ages (57 to 0 years of age). (2) The prevalence of psoriasis in Caucasians is 2 11%. (1) The prevalence of psoriasis in the United Kingdom (prevalence 1.3-2.%) and Spain (3) decreases markedly in patients over the age of 70 years. (2) Psoriasis is more prevalent in adults than in children and more prevalent in older children than in younger ones. In the USA, the prevalence of psoriasis increases more rapidly in young female patients compared with young male patients and declines significantly in patients 70 years and older, regardless of gender. (2) Psoriasis is less common in Mongoloid population. (4) The prevalence rate was more in south and northeast Europe than in the UK. In Latin America, India, Egypt, Tanzania, China, Sri Lanka and Taiwan, the prevalence rate was less than 0.5%. (4) Broadly, psoriasis is equally frequent in men and women. (1) In Taiwan, psoriasis is less common in women. (5) Patients with psoriasis had more co-morbidities in comparison with the general population. There is positive correlation between psoriasis and diabetes mellitus, hyperlipidaemia, hypertension and cardiovascular diseases. (-8) The occlusive vascular incidents are markedly more in patients with psoriasis than in the general population. (9) The aim of this study was to evaluate the demographics, therapeutic protocols, risk factors and co-morbidities of psoriasis in Jordan (public military health sector) Methods This prospective and observational study included 350 adult patients, of both genders, aged 19-75 years diagnosed with psoriasis and managed by dermatologists. Psoriasis was divided into a severe form if PASI score >10, and a mild form if PASI score <5. The patient's information (age, gender, medical illnesses (DM, HTN, hyperlipidemia, malignancy), drugs history, smoking, psychological illness, pregnancy) was used for the study during a period of 4 years from Jan 2012 to Jan 201 at Prince Rashid military hospital, Irbid, Jordan. The demographics, risk factors, therapeutic protocols and co-morbidities were assessed. We collected information on skin disorders and infections, pregnancy, stress, body mass index, smoking status and drug use (antihypertensive, antimalarial drugs, lithium, interferon's, NSAIDs, antibiotics, steroid withdrawal).the study was approved by the ethical and research review board committee of the Jordanian Royal Medical Services. Statistics The statistical significance in patient numbers between gender and various age groups was determined using chi-square test. Multiple logistic regression analysis was used to assess the correlation of co-morbidities with psoriasis according to age and gender. Odds ratios and 95% confidence interval were used to evaluate the correlation between co- morbidities and psoriasis. Results The study included 350 patients (192{54.9%} men and 158{45.1%} women, P>0.05) with a diagnosis of psoriasis. The number of psoriatic patients according to age and gender is shown in Table I. There was no marked sex discrepancy in the number of psoriatic Jordanian patients. The number of patients less than 27 years was comparable in both genders, but increased more in men aged 27-38 years, Table I.The maximum number was attained in Jordanian patients aged 8-75 years, in both genders, Table I. The number of psoriatic patients increased more in patients aged 8-75 years, in comparison with patients aged 59 7 7

years. Regarding multivariate analysis, mild psoriasis recorded OR 1.1(1.10-1.20) while severe psoriasis recorded OR 2.0(1.9-2.28). The therapeutic protocols of these 350 patients are demonstrated in Table II. Topical corticosteroids were the most commonly used drugs (94.9% of patients). Forty-five (12.9%) patients (29 men and 1 women) had systemic therapy (severe psoriasis), Table III. The incidence of patients using systemic therapy was more in males than in females {15.1 %( 29/192)} vs. {10.1 %( 1/158), respectively}. A total of 305 patients with mild psoriasis and 45 patients with severe psoriasis were recorded. Diabetes mellitus and hypercholesterolemia were correlated with psoriasis, Table IV. Gender and smoking (smoking: OR, 1.2 [95% CI, 1.1-1.4]) were independent risk factors for psoriasis in Jordan. Over weight patients had a mild effect on increasing the severity of the skin lesion and decreasing the improvement rate as well as smoking. History of any skin disorder diagnosis in the previous year was correlated with an OR of 3.1 (95% CI, 2.9-3.8). Having an episode of infectious disease in the last year increased the risk of psoriasis (OR, 1.8 [95% CI, 1.-2.1]). Infectious skin disorders were correlated with an OR of 1.7 (95% CI, 1.5-1.8). Pregnancy in the previous year was correlated with a reduced risk of psoriasis (OR, 0.4 [95% CI, 0.3-0.9]). Antibiotics (tetracycline's, penicillin, ampicillin) had an OR of 1.3 (95% CI, 1.1-1.5). There was no correlation with use of antihypertensive agents (beta-blocker, ACE inhibitors mainly) (OR, 0.7 [95% CI, 0.5-0.9]). Table V. Table I: Age and gender (number in relation with psoriasis) Gender 19-2 27-38 39-48 49-58 59-7 8-75 Total Male 15 19 28 3 40 54 192 Female 12 15 21 30 32 48 158 Table II: Therapeutic protocols in Jordanian patients with psoriasis. Therapeutic protocols Psoriatic patients (% and numbers) *Topical corticosteroids 94.9%(333) Tar preparations 35.2%(122) Vitamin D analogues 19.9%(70) Keratolytic agents 13.5%(47) Calcineurin inhibitors 0.1%(3) *Ultraviolet light therapy : 15.2%(53) UVB ( ultraviolet B 290-320nm ) n BUVB ( narrow band ultraviolet 10.5%(37) B 311-313nm) PUVA ( psoralen with ultraviolet 4.7%(1) radiation A ) Targeted phototherapy ( UVB delivered with the laser system, Excimer308 nm ) *Systemic treatments 12.9%(45) Methotrexate.1%(21) Systemic retinoid ( Acitretin ) 4.%(1) Cyclosporin A 1.7%() Biologic therapy 0.0%(2) TNF inhibitors: Etanercept 0.0%(2) Infliximab Adalimumab IL12&23 Inhibitors: Ustekinumab Anti pathogenic T cells Agents: Alefacept Efalizumab 8

Table III: Age and gender of Patients with severe psoriasis. Gender 19-2 27-38 39-48 49-58 59-7 8-75 Male 3.7% 4 8.9% 4 8.9% female 1 2.2% 3.7% 3.7% 5 11.1% 2 4.4% 2 4.4% Table VI: Correlation between co- diseases and mild or severe psoriasis. Multivariate analysis Mild psoriasis OR(95% CI) Severe psoriasis OR(95% CI) Coronary artery disease 0.9(0.8-1.28) 0.8(0.78-1.21) Hypertension 0.8(0.7-1.27) 0.95(0.85-1.42) Hypercholesterolemia 1.9(1.7-2.1) 1.8(1.8-2.5) Occlusive vascular incidents 0.95(0.83-1.29) 0.85(0.80-1.4) Diabetes mellitus 1.8(1.02-1.95) 1.9(1.35-2.0) Table V: Correlation between risk factors and OR. Factor OR (95%:CI) PSORIASIS NUMBER Skin Disorders 3.1(2.9-3.8) Increased Skin Infections 1.7(1.5-1.8) Increased Smoking 1.2(1.1-1.4) Decreased Infectious Diseases 1.8(1.-2.1) Increased Pregnancy 0.4(0.3-0.9) Decreased Antibiotics 1.3(1.1-1.5) Decreased Antihypertensives 0.7(0.5-0.9) Decreased Discussion Psoriasis is an immune genetically frequent skin disease, affecting skin, nails and joints with different systemic implications. Psoriasis is characterized by erythematous papules and plaques with silvery scale that affect any skin surface. It is a chronic inflammatory skin disease with increased epidermal proliferation. The types of psoriasis include: plaque, inverse (flexural), erythrodermic, pustular and guttate type. (10) Psoriasis has adetrimental effect on quality of health and on economic aspect. Our investigation evaluated therapeutic protocols, risk factors and co- morbidities for psoriasis. Psoriasis has strong genetic relation. The risk for having psoriasis is 4% if the parents of the person do not have psoriasis. The risk increases to 28% if one of the parents is affected and to 5% if both parents are affected. (9) According to the gender of the carrier, it is increased if the carrier is the father. Psoriasis is autosomal dominant with recessive gene traits. Psoriasis expresses traits by 3 to 4 autosomal dominant genes while one gene acts in a recessive manner. Early onset psoriasis with severe progression is correlated with human leukocyte antigen (HLA-A2, B17, B37, HLA-CW, and DR7) factors whereas the milder, late onset form is not. The low prevalence of psoriasis worldwide is may be due to a low incidence of HLA-Cw. (1) Although worldwide, psoriasis does not have a gender bias, in our Jordanian patients with psoriasis there were more males than females. In China, psoriasis is more frequent in males than in females. (4) In Caucasian people, the prevalence of psoriasis decrease markedly in patients above 70 years of age. (2,3) Our results found that psoriasis increased more in Jordanian patients aged 8-75 years, compared with patients aged 59 7 years. Older patients in Jordan may be at increased risk for having new onset psoriasis. This study demonstrated that the majority (94.9%) of patients had topical corticosteroid therapy. Diabetes mellitus and hypercholesterolemia were correlated risk factors in Jordanian patients with psoriasis. The severity of psoriasis is increased with smoking and with high body mass index, (11,12) obese patients are more likely to have severe psoriasis 9

and smoking decreases the response to the medication used for psoriasis, (13,14) also stressful life events (12) and depression increase the risk of psoriasis. (15) To enhance diagnostic precision and exclude over estimation of the prevalence of psoriasis, our study concentrated on psoriasis patients managed by dermatologists. As patients with mild psoriasis may not have been seen by a specialist during the 4 -year study period, the prevalence of mild psoriasis may be under estimated. There is a correlation between psoriasis and infectious diseases. Streptococcal infection is a risk factor for psoriasis in young people. There is a high risk of psoriasis in patients with new infectious disease, and the risk is more during the first month after an upper respiratory tract infection among persons aged 21 to 40 years. (5) Conclusion Psoriasis in the Jordanian population attending a public health military sector was more common in males than females and the number increased markedly in patients above 7 years References 1. World health organization. Global report on psoriasis. 201. pp.1-3. 2. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537 1541. 3. Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr 2014; 105(5): 504-509. 4. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984; 10: 95 98. 5. Chang YT, Chou CT, Yu CW, et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 2007; 15: 899 905.. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an inter disciplinary conference and review. Br J Dermatol 2007; 157: 49 55. 7. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors inpatients with psoriasis. J Am Acad Dermatol 200; 55: 829 835. 8. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001 2002. Dermatology 2008; 217: 27 37. 9. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 200; 29: 1735 1741. 10. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007;15:258-22. 11. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527 1534. 12. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 1 7. 13. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559 155. 14. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175:402 413 15. Dominguez PL, Han J, Li T, Ascherio A, Qureshi AA. Depression and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013; 27(9):113 117. Published online 2012 Oct 3. 10